Black Rock Inc. Akebia Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 11,638,484 shares of AKBA stock, worth $21.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,638,484
Previous 2,539,225
358.35%
Holding current value
$21.4 Million
Previous $4.65 Million
155.51%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding AKBA
# of Institutions
120Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Vanguard Group Inc Valley Forge, PA10.1MShares$18.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.6 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$8.75 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$6.84 Million0.01% of portfolio
-
State Street Corp Boston, MA3.43MShares$6.31 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $338M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...